Adjuvant Therapy for Urothelial and Renal Cell Carcinoma.
Adjuvant therapy for urothelial and renal cell carcinoma has progressed steadily over the past 30 yr. Level 1 evidence supports a role for both neoadjuvant and adjuvant cisplatin-based chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Recent evidence has also confirmed a benefit from adjuvant therapy in high-grade upper tract urothelial carcinoma. Adjuvant targeted therapy remains controversial and outside the standard of care for renal cell carcinoma, with no proven overall survival benefit. Immune checkpoint blockade is poised to shift the landscape for both urothelial and renal cell carcinoma with the potential for greater efficacy.